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Abstract
Background: Sudden cardiac death (SCD) is the most common etiology of death in hemodialysis patients but not
much is known about its risk factors. The goal of our study was to determine the association and risk prediction of
SCD by serum N-terminal prohormone of brain natriuretic peptide (NTproBNP) troponin I (cTnI) in hemodialysis
patients.
Methods: We measured NTproBNP and cTnI in 503 hemodialysis patients of a national prospective cohort study.
We determined their association with SCD using Cox regression, adjusting for demographics, co-morbidities, and
clinical factors and risk prediction using C-statistic and Net Reclassification Improvement (NRI).
Results: Patients’ mean age was 58 years and 54 % were male. During follow-up (median 3.5 years), there were 75
outpatient SCD events. In unadjusted and fully-adjusted models, NTproBNP had a significant association with the
risk of SCD. Analyzed as a continuous variable, the risk of SCD increased 27 % with each 2-fold increase in
NTproBNP (HR, 1.27 per doubling; 95 % CI, 1.13–1.43; p < 0.001). In categorical models, the risk of SCD was 3-fold
higher in the highest tertile of NTproBNP (>7,350 pg/mL) compared with the lowest tertile (<1,710 pg/mL; HR for
the highest tertile, 3.03; 95 % CI, 1.56–5.89; p = 0.001). Higher cTnI showed a trend towards increased risk of SCD in
fully adjusted models, but was not statistically significant (HR, 1.17 per doubling; 95 % CI, 0.98–1.40; p = 0.08).
Sensitivity analyses using competing risk models showed similar results. Improvement in risk prediction by adding
cardiac biomarkers to conventional risk factors was greater with NTproBNP (C-statistic for 3-year risk: 0.810; 95 % CI,
0.757 to 0.864; and continuous NRI: 0.270; 95 % CI, 0.046 to 0.495) than with cTnI.
Conclusions: NTproBNP is associated with the risk of SCD in hemodialysis patients. Further research is needed to
determine if biomarkers measurement can guide SCD risk prevention strategies in dialysis patients.
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Background
At least one-quarter of deaths in dialysis patients are es-
timated to be from sudden cardiac death (SCD) [1]. This
increased risk of SCD in dialysis patients is likely af-
fected by the multiple, associated co-morbid conditions,
such as diabetes [2] and hypertension [3], left ventricular
hypertrophy [4], ischemic heart disease [5], inflammation
[6] and perhaps the dialysis treatment itself with inter-
mittent fluid and electrolyte fluctuations [2].
A large gap of knowledge still remains as to which dia-
lysis patients are at the highest risk of suffering SCD.
Cardiac biomarkers may identify patients with subclin-
ical cardiovascular disease that are at increased risk for
SCD. The N-Terminal fragment of the pro-hormone
brain natriuretic peptide (NTproBNP) is a marker of
myocardial stretch and volume overload [7]. Serum car-
diac troponin I (cTnI) is a marker of cardiac damage. El-
evated cTnI levels in dialysis patients are associated with
increased risk of all-cause and cardiovascular mortality,
but few studies have investigated the association be-
tween these biomarkers and SCD in hemodialysis pa-
tients [8, 9].
The aim of our study was to determine if elevated
levels of NTproBNP and cTnI are associated with in-
creased risk for SCD in hemodialysis patients. We also
evaluated whether these cardiac makers improve the risk




The Choices for Healthy Outcomes in Caring for ESRD
(CHOICE) Study is a longitudinal, prospective cohort
study of 1041 patients starting dialysis that were re-
cruited from 81 dialysis centers in 19 states. Eligibility
criteria included dialysis initiation in preceding 3 months,
age 18 years or older, ability to speak English or Spanish,
and ability to consent. Each participant completed in-
formed consent. The participants were enrolled from
October 1995 to June 1998 and were on average 45 days
post-dialysis initiation. A specimen bank was established
for all Dialysis Clinic, Inc. (DCI) participants. Our ana-
lysis included 503 hemodialysis participants with avail-
able stored specimens. The Johns Hopkins Medicine
Institutional Review Board and the clinical centers’ re-
view boards approved the study and all participants pro-
vided informed consent.
Cardiac biomarkers (Serum NTproBNP and cTnI)
We collected blood samples prior to routine outpatient
dialysis session, centrifuged within 30–45 min of collec-
tion, and sent them overnight on ice to the central la-
boratory. We divided each sample into multiple vials
and stored at −80 °C till they were thawed and aliquoted
for this study. We measured NT-pro-BNP using a one-
step sandwich chemiluminescent immunoassay also
based on LOCI* technology. We measured cTnI by
homogeneous, sandwich chemiluminescent immuno-
assay based on LOCI* technology. Both NTproBNP and
cTnI were measured on the Dimension Vista System at
the University of Maryland School of Medicine, Balti-
more, Maryland. The coefficient of variation (CV) for
NT-pro-BNP was 5.0 % at 107.2 pg/mL and 1.6 % at
275 pg/mL and 1.2 % at 3,313 pg/mL. The reliability cor-
relation coefficient for NT-pro-BNP was 0.998. The CV
for cTnI was 9.1 % at 0.090 ng/mL, 5.9 % at 1.08 ng/mL
and 1.6 % at 4.87 ng/mL. The reliability correlation coef-
ficient for cTnI in a 5 % sample of masked duplicate
specimens was 0.969.
Outcome
The primary outcome for this study was outpatient SCD
defined as an out-of-hospital deaths including deaths
that occurred in an emergency department or one in
which the patient was reported to be “dead on arrival”
with the following codes noted in the National Death
Index death certificate data: ICD-9 390–398, 402 or
404–429; and ICD-10, I00-I09, I11, I13 and I20–I51, as
previously described [6]. We excluded deaths with
hyperkalemia, sepsis or malignancy listed as a contribut-
ing cause of death or if the death occurred while under
hospice care.
Other covariates
We collected data on participants’ age, sex, race and
body mass index (BMI). We adjudicated baseline comor-
bidities including prevalent cardiovascular disease and
left ventricular hypertrophy (as assessed by electrocar-
diograms) by abstraction of dialysis unit records, hos-
pital discharge summaries, medication lists, consultation
notes, diagnostic imaging, and cardiac imaging reports
and Index of Coexistent Disease (ICED) scoring. For this
index, comorbid conditions, including diabetes mellitus,
ischemic heart disease, congestive heart failure, hyper-
tension, peripheral vascular disease, and other condi-
tions, were determined present by two trained nurses,
and then, the severity of each comorbid condition for
each patient was calculated using Index of Disease
Severity (IDS) and Index of Physical Impairment (IPI)
(30). These two scores were then used to calculate the
ICED score, which serves as a validated medical record-
derived index that captures both presence and severity
of comorbid conditions19,20,30. ICED scores range from 0
to 3, with 3 as the highest severity level. We abstracted
antihypertensive medication use at baseline from pa-
tients’ charts and obtained routine laboratory data from
medical records. We measured serum albumin (CV,
1.9 %) in the same specimen as NTproBNP and cTnI at
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University of Minnesota, Minneapolis, Minnesota. We
also used data on C-reactive protein, interleukin-6 and
p-selectin that had been previously measured for
research [10, 11]. Other laboratory data measured in
routine clinical care included hemoglobin, calcium,
phosphate, blood urea nitrogen, creatinine, glucose,
potassium and bicarbonate. These laboratory data were
obtained from the same time as cardiac biomarker
assessment.
Statistical analysis
We compared the baseline characteristics of the partici-
pants across categories of NTproBNP and cTnI using
chi-squared test for categorical variables and t-tests for
continuous variables. Missing data for variables were as
follows: educational status (2.8 %), smoking history
(2.8 %), BMI (5.6 %) systolic blood pressure (3.8 %),
serum potassium, calcium and phosphate (6.8 %) and
serum bicarbonate (12 %). Missing data values were im-
puted with 10 data replicates using multiple imputation
by the chained equations method implemented by the
ice program in Stata. We modeled NTproBNP and cTnI
as continuous variables after natural log transformation
and as categorical variables. We categorized NTproBNP
as tertiles and cTnI as a low, mid and high category. The
low cTnI group included those with cTnI below detec-
tion limit; (<0.015 ng/mL; n = 336). Remaining patients
are divided into two groups at the median with the mid
category referring to group with detectable values but
below median (<0.040 ng/mL; n = 85) and high category
referring to the group with values at or above median
(≥0.040 ng/mL; n = 82). We visualized the association
between NTproBNP and cTnI and outcomes by calculat-
ing incidence rates for SCD adjusted for age, sex and
race using a Poisson regression model with biomarkers
modeled as linear spline with 2 knots corresponding to
the categories. We used Cox proportional hazards re-
gression to analyze the association between the bio-
markers and SCD. We assessed proportional hazards
assumptions graphically and by tests of Schoenfeld resid-
uals. We used hazard ratios (HRs) to quantify the associ-
ations of biomarkers with SCD after adjustment for a
priori defined confounders, including demographic char-
acteristics [age, sex, race (white or other)] and clinical
factors [smoking status (ever versus never), ICED score,
diabetes, cardiovascular disease, left ventricular hyper-
trophy, congestive heart failure, BMI and systolic blood
pressure], laboratory tests (hemoglobin, serum albumin,
serum potassium, serum bicarbonate, serum corrected
calcium and serum phosphate) and β-blocker use. We
conducted sensitivity analyses further adjusting for bio-
markers previously associated with SCD in CHOICE
study (i.e., CRP, IL-6, and p-selectin) and accounting for
the competing risk of death from other causes using
competing-risks regression based on Fine and Gray’s
proportional subhazards model. In exploratory analyses
we further determined SCD risk association within sub-
groups by testing for interactions with age, sex, race,
cardiovascular disease, diabetes, serum albumin, serum
potassium and serum bicarbonate, with continuous
variables categorized above or below median. We evalu-
ated risk prediction by NTproBNP and cTnI over 5-
years by calculating C statistic and net reclassification
improvement (NRI) [12, 13]. We assessed model calibra-
tion using modified Hosmer–Lemeshow statistic [14,
15]. We performed all statistical analyses using Stata
software, version 12.1 (Stata Corp.). We defined statis-
tical significance as p <0.05 using two-tailed tests.
Results
Baseline characteristics
The final study sample comprised of 503 hemodialysis
patients. Compared to the overall cohort, the included
patients were less likely to be White and had higher urea
creatinine, potassium, calcium, phosphate and albumin
and lower hemoglobin and Kt/Vurea (Additional file 1:
Table S1). The average age of the participants was
58 years and 54 % were men. At baseline, 57 % of the
participants had diabetes, 56 % had cardiovascular dis-
ease, and 24 % had a history of myocardial infarction.
Table 1 summarizes the baseline characteristics of the
participants according to categories of NTproBNP and
cTnI. Patients with higher NTproBNP and cTnI were
older, more likely to have a history of cardiovascular dis-
ease, and have elevated IL-6 levels. In addition, patients
with higher NTproBNP were more likely to be White,
had lower body BMI and higher CRP whereas those with
higher cTnI were more likely to be male.
Association of NTproBNP and cTnI with SCD
The 75 SCD events occurred over 1,814 person-year of
follow-up (median 3.5 years) with an incidence rate of
41.4 SCD events over 1000 person-years. The causes of
death in these 75 patients, cross-tabulated by the causes
listed in the National Death Index and Center for Medi-
care and Medicaid Services (CMS) death notification
form (Form 2746) are presented in Additional file 1:
Table S2. Fig. 1 presents the incidence rate of SCD ad-
justed for age, sex and race, demonstrating a linear
increase in SCD incidence rate with NTproBNP and a
relatively flat association with cTnI. In unadjusted
models and minimally adjusted models, both NTproBNP
and cTnI were associated with risk of SCD (Table 2).
After adjustment for demographics, clinical factors,
comorbidities, laboratory tests and β-blocker use,
NTproBNP continued to have a statistically significant
association [HR, 95 % confidence interval (CI)] with
SCD [1.27 (1.13–1.43); p < 0.001]] whereas as the
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Table 1 Characteristics of 503 Hemodialysis Patients by Levels of NTproBNP and cTnI
NTproBNP (pg/mL) Categories Troponin I (ng/mL) Categories
Below Detection Limit Detectable
Characteristic Overall Low Mid High p Low Mid High p
Range, minimum
to maximum
59–1710 1728–7269 7350–273502 - <0.015 0.015–0.039 0.04–3.09 -









3138(1233–9835) 822.5(489.5–1238) 3145.5(2364–4622) 14735(9835–24240) - 2205(945–5670.5) 7166(2326–16018) 10242(4187–23407) -
Demographics
Age, years 57.8 (14.7) 52.7 (13.8) 59.8 (15.2) 60.9 (13.6) <0.001 56.1 (15.4) 60.3 (13.1) 62.1 (11.9) <0.001
White 321 (63.8) 99 (58.9) 101 (60.1) 121 (72.5) 0.017 225 (67.0) 50 (58.8) 46 (56.1) 0.107





27.4 (7.1) 28.2 (7.8) 28.1 (7.5) 25.8 (5.6) 0.002 27.6 (7.3) 27.0 (6.7) 26.9 (6.9) 0.297
Cause of End
Stage Renal Disease
Diabetes mellitus 248 (49.3) 77 (45.8) 82 (48.8) 89 (53.3) 0.389 157 (46.7) 46 (54.1) 45 (54.9) 0.259
Hypertension 86 (17.1) 21 (12.5) 27 (16.1) 38 (22.8) 0.041 50 (14.9) 18 (21.2) 18 (22.0) 0.172
Glomerulonephritis 74 (14.7) 36 (21.4) 25 (14.9) 13 (7.8) 0.002 58 (17.3) 9 (10.6) 7 (8.5) 0.068
Other 95 (18.9) 34 (20.2) 34 (20.2) 27 (16.2) 0.547 71 (21.1) 12 (14.1) 12 (14.6) 0.189
ICED = 3 147 (29.3) 41 (24.4) 46 (27.5) 60 (35.9) 0.057 97 (29.0) 20 (23.5) 30 (36.6) 0.175
Diabetes 287 (57.2) 85 (50.6) 95 (56.9) 107 (64.1) 0.045 180 (53.7) 54 (63.5) 53 (64.6) 0.087
Cardiovascular
Disease
279 (55.6) 64 (38.1) 102 (61.1) 113 (67.7) <0.001 165 (49.3) 58 (68.2) 56 (68.3) <0.001
Congestive
Heart Failure
247 (49.2) 58 (34.5) 80 (47.9) 109 (65.3) <0.001 146 (43.6) 54 (63.5) 47 (57.3) 0.001
Coronary Heart
Disease
209 (41.6) 42 (25) 77 (46.1) 90 (53.9) <0.001 114 (34.0) 47 (55.3) 48 (58.5) <0.001
Myocardial
Infarction
120 (23.9) 20 (11.9) 51 (30.5) 49 (29.3) <0.001 68 (20.3) 23 (27.1) 29 (35.4) 0.012
Left Ventricular
Hypertrophy




















57.8 (15.1) 57.6 (15.3) 58.3 (15.4) 57.6 (14.8) 0.998 57.3 (15.5) 59.3 (14.9) 58.4 (14.1) 0.482
Kt/VUREA 1.3 (0.302) 1.3 (0.324) 1.3 (0.278) 1.3 (0.303) 0.250 1.3 (0.316) 1.3 (0.255) 1.3 (0.292) 0.788
Creatinine,
mg/dL
8.0 (2.9) 8.2 (2.8) 8.2 (3.2) 7.6 (2.5) 0.081 8.1 (2.9) 7.9 (2.7) 7.6 (2.8) 0.311
Potassium, mEq/L 4.7 (0.665) 4.6 (0.584) 4.7 (0.712) 4.7 (0.680) 0.036 4.7 (0.642) 4.7 (0.689) 4.7 (0.733) 0.665
Glucose, mg/dL 167.0 (103.0) 162.3 (79.0) 164.0 (82.7) 174.8 (137.2) 0.780 159.9 (83.4) 178.4 (120.0) 183.9 (145.3) 0.222
Bicarbonate,
mEq/L
20.4 (2.9) 20.7 (2.7) 20.0 (3.0) 20.5 (2.9) 0.510 20.4 (2.9) 20.7 (2.5) 20.2 (3.4) 0.919
Hemoglobin,
g/dL
11.0 (1.3) 11.2 (1.5) 10.9 (1.3) 10.8 (1.3) 0.003 11.0 (1.4) 11.2 (1.2) 10.8 (1.4) 0.686
Corrected
Calcium, mg/dL
9.8 (0.883) 9.7 (0.854) 9.8 (0.954) 9.8 (0.839) 0.471 9.8 (0.881) 9.8 (0.918) 9.6 (0.844) 0.050
Phosphate, mg/dL 5.5 (1.7) 5.5 (1.6) 5.5 (1.8) 5.6 (1.6) 0.348 5.5 (1.7) 5.8 (1.6) 5.6 (1.9) 0.283




0.445(0.203–1.219) 0.382(0.158–0.779) 0.486(0.224–1.317) 0.51
(0.217–1.496)
0.007 0.441(0.195–1.229) 0.431(0.148–1.04) 0.489(0.222–1.155) 0.980
IL-6, pg/mL
(median, 25th – 75th
percentiles)
4.8 (2.8–8.2) 3.8 (2.3–5.6) 5.2 (2.7–8.9) 6.2 (3.6–11.5) <0.001 4.3 (2.6–7.4) 5.3 (3.4–9.0) 6.1 (3.6–11.7) 0.008
P-Selectin, ng/ml
(median, 25th – 75th
percentiles)
97.2(75.6–126.0) 93.4(74.0–125.9) 96(73.9–124.1) 98.7(79.4–130.2) 0.526 96.3(76.2–127.7) 94.7(72.2–117.0) 105.5(78.2–124.5) 0.627
Antihypertensive
Medications, %
β-blockers 123 (24.5) 36 (21.4) 40 (23.8) 47 (28.1) 0.350 84 (25.0) 21 (24.7) 18 (22.0) 0.846
ACE-inhibitors 147 (29.2) 40 (23.8) 51 (30.4) 56 (33.5) 0.136 87 (25.9) 29 (34.1) 31 (37.8) 0.058
Calcium Channel
Blockers
309 (61.4) 105 (62.5) 109 (64.9) 95 (56.9) 0.304 205 (61.0) 60 (70.6) 44 (53.7) 0.077
Abbreviations: Troponin I, TNI; Hazard Ratio, HR; N-terminal pro-brain natriuretic peptide, NTproBNP
For TNI, low category refers those patients with TNI below the limit of detection (<0.015 ng/mL; n = 336). Remaining patients are divided into two groups at the median. Mid category refers to the group below median
TNI for those with detectable values (<0.040 ng/mL; n = 85) and high category refers to those with values at or above median (≥0.040 ng/mL; n = 82)
For NTproBNP, low, mid and high category refers to the lowest, middle and highest tertiles of NTproBNP












association between cTnI and SCD was not statistically
significant [1.17 (0.98–1.40); p = 0.08]. Similar results
were noted in the categorical analysis (Table 2). In the
fully adjusted models, compared to the lowest tertile of
NTproBNP, those in the highest tertile had a more than
3-fold higher risk of SCD [3.03 (1.56–5.89); p = 0.001].
Compared to the low cTnI category (undetectable cTnI),
those in the mid (detectable and below median) and
high cTnI category (detectable and above median) had a
non-significant trend towards increased risk of SCD in
the fully adjusted models.
Sensitivity analyses of the association between NTproBNP
and cTNI and SCD
Further adjustment for markers of inflammation (CRP,
IL6 and p-selectin) did not significantly change the mag-
nitude or the direction of association (data not pre-
sented). Analyses using competing risks models showed
results similar to the primary analysis (Additional file 1:
Table S3).
Exploratory analyses of the association between
NTproBNP and cTnI and SCD
The subgroup analyses should be interpreted with cau-
tion due to small sample size and multiple comparisons.
There were no significant interactions in the models for
NTproBNP (Fig. 2a) but there was suggestion of effect
modification by cTnI and sex (p-interaction =0.02), base-
line cardiovascular disease (p-interaction =0.01), serum
albumin (p-interaction =0.008), serum potassium (p-
interaction = 0.01) and bicarbonate (p-interaction = 0.02).
Risk prediction of SCD with NTproBNP and cTnI
Compared to the fully adjusted model, the improvement
in 3-year and 5-year risk prediction was greater with
NTproBNP than cTnI (Table 3). Addition of both
NTproBNP and cTnI to the model did not lead to fur-
ther improvement in risk prediction.
Discussion
In this national prospective cohort study of incident dia-
lysis patients, we found a significant association between
NTproBNP levels and the risk of outpatient SCD. Pa-
tients in the highest tertile of NTproBNP (>7,350 pg/
mL) had a more than 3-fold higher risk of SCD com-
pared with those in the lowest tertile (<1,710 pg/mL).
NTproBNP also improved risk prediction of SCD with
improvement in 3-year and 5-year NRI. Higher cTnI
(>0.04 ng/mL) was also associated with a 91 % higher
risk of SCD although it was of borderline statistical
significance.
NTproBNP is a marker of myocardial stretch and cor-
relates with reduced left ventricular function and volume
overload in dialysis patients [3, 16, 17]. A number of
previous studies have reported the association between
elevated NTproBNP and cTnI and all-cause and cardio-
vascular mortality [18–20]. However, only a few prior
studies have studied the association between these
markers and SCD in dialysis patients. In the German
Diabetes and Dialysis Study (4D-Study), NTproBNP
above the fourth quartile (≥9,252 pg/mL) was associated
with 2-fold higher risk of SCD compared with the lowest
quartile. However, the study only included patients with
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Fig. 1 Adjusted incidence rate of sudden cardiac death in 503 participants of the CHOICE Study. Incidence rate per 100 person years adjusted
for age, sex and race. Results are presented separately for (a) N-terminal pro-brain natriuretic peptide (NTproBNP) and (b) cardiac troponin I
(cTnI). Line represents hazard ratio and shaded area represents the 95 % confidence interval. Vertical bars represent the distribution of the
biomarkers. Data are limited to ≥0.5th percentile and ≤99.5th percentiles
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Table 2 Association of NTproBNP and cTnI with Sudden Cardiac Death among 503 Hemodialysis Patients of the CHOICE Study
Model 1 Model 2 Model 3 Model 4
Range N (events) CrudeIR HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p
NTproBNP, pg/mL
Continuous a 503 (75) 1.33 (1.21–1.46) <0.001 1.29 (1.17–1.42) <0.001 1.28 (1.14–1.44) <0.001 1.27 (1.13–1.43) <0.001
Categorical b, d
Low Category 59–1710 168 (13) 19.0 Reference Reference Reference Reference
Mid Category 1728–7269 168 (22) 35.3 1.99 (1.25–3.14) 0.003 1.99 (1.16–3.41) 0.012 1.67 (1.01–2.77) 0.045 1.39 (0.79–2.44) 0.252
High Category 7350–273502 167 (40) 78.9 4.49 (2.61–7.71) <0.001 3.90 (2.07–7.34) <0.001 3.32 (1.67–6.59) 0.001 3.03 (1.56–5.89) 0.001
p-trend <0.001 <0.001 0.001 0.001
Troponin I, ng/mL
Continuous a 503 (75) 1.19 (1.06–1.32) 0.002 1.22 (1.07–1.38) 0.002 1.18 (1.02–1.36) 0.027 1.17 (0.98–1.40) 0.084
Categorical b, c
Low Category <0.015 336 (41) 32.8 Reference Reference Reference Reference
Mid Category 0.015–0.039 85 (18) 57.5 1.82 (1.06–3.10) 0.029 1.83 (1.04–3.20) 0.036 1.56 (0.88–2.80) 0.128 1.62 (0.89–2.95) 0.11
High Category 0.040–3.09 82 (16) 64.0 2.14 (1.46–3.13) <0.001 2.48 (1.51–4.06) <0.001 1.98 (1.15–3.39) 0.013 1.91 (0.98–3.72) 0.058
p-trend <0.001 <0.001 0.011 0.048
Abbreviations: Troponin I, cTnI; Hazard Ratio, HR; N-terminal pro-brain natriuretic peptide, NTproBNP. Incidence rate per 1000 person-years
a Hazard ratio per doubling of the marker; modeled as ln(marker)/ln(2). Modeled using Cox proportional hazards regression
b Hazard ratio with the low category as the reference group. Modeled using Cox proportional hazards regression
c For cTnI, low category refers those patients with TNI below the limit of detection (<0.015 ng/mL; n = 336). Remaining patients are divided into two groups at the median. Mid category refers to the group below
median cTnI for those with detectable values (<0.040 ng/mL; n = 85) and high category refers to those with values at or above median (≥0.040 ng/mL; n = 82)
d For NTproBNP, low, mid and high category refers to the lowest, middle and highest tertiles of NTproBNP
Model 1: Unadjusted
Model 2: Adjusted for demographics including age, sex and race
Model 3: Adjusted for variables in model 2 + clinical factors including smoking status (ever versus never), Index of Coexistent Disease (ICED) score, diabetes, cardiovascular disease, congestive heart failure, body mass
index and systolic blood pressure













NTproBNP but not troponin T was associated with an
increased risk of SCD [3]. Our study extends these find-
ings to a national cohort of US dialysis patients and
shows a stronger association of NTproBNP compared
with cTnI with SCD.
cTnI is an inhibitory protein within the troponin-
tropomyosin complex that regulates striated muscle
contraction [21]. The troponin complex is released in
damaged cardiac muscle and serum levels are
sensitive markers of cardiac injury [21, 22]. In our
study, the findings of weaker association between
cTnI and SCD compared with NTproBNP could
reflect a greater risk of arrhythmia and SCD with vol-
ume overload and ventricular stretch detected by
Fig. 2 Subgroup analysis of the association between (a) NTproBNP and (b) cTnI and sudden cardiac death in 503 participants of the CHOICE
Study. Hazard ratios are adjusted for variable in Model 4: demographics (age, sex and race), clinical factors [smoking status (ever versus never),
Index of Coexistent Disease (ICED) score, diabetes, cardiovascular disease, congestive heart failure, body mass index and systolic blood pressure],
left ventricular hypertrophy, β-blocker use and laboratory tests including hemoglobin, serum albumin, serum potassium, serum bicarbonate,
serum corrected calcium and serum phosphate
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NTproBNP versus elevation of cTnI which could be
from myocardial injury but could also reflect
decreased renal clearance [23]. In previous dialysis
studies, prevalence of elevated cTnI is lower than
prevalence of elevated troponin T [18] and elevated
cTnI levels have been inconsistently associated with
increased risk of death. [23, 24] Whether these find-
ings represent biological associations or the effect of
assay variability at the low threshold will require
future studies with comparison of different cTnI assay
techniques, including the high-sensitivity troponin I
assays [25].
In addition to evaluating NTproBNP and cTnI as a
risk factor for SCD, we assessed its role in improving
risk prediction. To our knowledge, prior studies of
cardiac biomarkers in hemodialysis patients have not
assessed improvement in risk prediction by cardiac
biomarkers over traditional risk factors. In a study by
Goldstein et al. using electronic medical record data,
blood pressure, ultrafiltration and serum albumin pre-
dicted short-term (within a day of last outpatient
hemodialysis) SCD in dialysis patients but cardiac bio-
markers were not measured. [26] The rate of SCD in
dialysis patients, 41 per 1000 person-years in our
study, was substantially higher than that reported in
the general population [27]. Implantable cardioverter-
defibrillators (ICDs) can prevent SCD but are associ-
ated with a higher risk of infection [28, 29]. There
are no randomized controlled data to guide primary
prevention ICDs in this high risk population. Im-
provement in risk prediction of SCD by NTproBNP
may help with identifying the patients at highest risk
of SCD and facilitate their enrollment in future trials
of SCD prevention.
There are some limitations to our study. First, we
had a single measurement of biomarkers in stored
specimens. The serum concentrations in individuals
may change over time and the long storage time may
effect serum concentrations. Second, our definition of
SCD was based on location at time of death and the
results may not apply to inpatient deaths many of
which may be due to ventricular arrhythmias. The
proportion of SCD was lower in our cohort (75/503;
15 %) versus that reported by USRDS (26.5 %). This
could be due to difference in SCD definition
(Additional file 1: Table S4) or due to relatively
healthier patients in our cohort that survived to
~6 months when blood samples were obtained. Exclu-
sion of inpatient deaths is likely to underestimate the
risk. Third, patients with available samples may have
been in better health compared to the overall cohort
as they had higher baseline serum albumin and cre-
atinine than included patients. It is possible that the
associations may have been even stronger in the full
cohort. Finally, even though we adjusted for a number
of confounders, the possibility of uncontrolled con-
founding remains from factors, such as echo or mag-
netic resonance imaging based left ventricular mass
and dialysate composition, which were not available
in this study. These limitations are counterbalanced
by our prospective study design with detailed assess-
ments of baseline comorbidities complete and exten-
sive information on covariates and inflammatory
markers which are not available on most registry
based retrospective dialysis cohorts. The use of NDI
data rather than Form 2746 data is also an important
strength of this study. Form 2746 is filled out by the
primary nephrologist in the dialysis unit, sometimes
Table 3 Risk Prediction for Sudden Cardiac Death with NTproBNP and cTnI in 503 Hemodialysis Patients of the CHOICE Study
Model 4a +NTproBNP +cTnI +NTproBNP and cTnI
3-Year Risk
C-Statistic 0.790 (0.728 to 0.851) 0.810 (0.757 to 0.864) 0.791 (0.732 to 0.849) 0.810 (0.756 to 0.864)
Change in C-Statisticb Ref 0.020 (−0.016 to 0.057) 0.001 (−0.019 to 0.021) 0.020 (−0.017 to 0.057)
NRI, Binary Ref 0.125 (0.032 to 0.219) 0.033 (−0.021 to 0.088) 0.133 (0.039 to 0.227)
NRI, Continuous Ref 0.262 (−0.048 to 0.572) 0.125 (−0.186 to 0.436) 0.212 (−0.098 to 0.522)
5-Year Risk
C-Statistic 0.773 (0.723 to 0.823) 0.797 (0.751 to 0.843) 0.778 (0.730 to 0.827) 0.797 (0.751 to 0.843)
Change in C-Statistic Ref 0.024 (−0.004 to 0.053) 0.006 (−0.009 to 0.021) 0.024 (−0.005 to 0.053)
NRI, Binary Ref 0.063 (−0.028 to 0.154) 0.001 (−0.065 to 0.067) 0.072 (−0.020 to 0.164)
NRI, Continuous Ref 0.270 (0.046 to 0.495) 0.018 (−0.207 to 0.243) 0.356 (0.132 to 0.581)
Abbreviations: SCD sudden cardiac death; NTproBNP, and N-terminal prohormone of brain natriuretic peptide; cTnI cardiac troponin I; CVD cardiovascular disease;
DM diabetes mellitus; C-statistic, concordance statistic, NRI net reclassification index
a Model 4: Adjusted for demographics (age, sex and race), clinical factors [smoking status (ever versus never), Index of Coexistent Disease (ICED) score, diabetes,
cardiovascular disease, congestive heart failure, body mass index and systolic blood pressure], left ventricular hypertrophy, β-blocker use and laboratory tests
including hemoglobin, serum albumin, serum potassium, serum bicarbonate, serum corrected calcium and serum phosphate
b Change in C-statistic by adding biomarker to the variables in Model 4
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weeks after death, and they may not know of the cause of
death. NDI uses death certificate data which is from pro-
viders who were closer to patients’ care at the time of
death. This approach reduces the risk of misclassification
of outcomes (Additional file 1: Table S2).
Conclusions
In conclusion, our study demonstrates a significant asso-
ciation between NTproBNP and SCD and suggests that
elevated NTproBNP level in dialysis patients is a potent
predictor for SCD. SCD is a potentially modifiable cause
of death in dialysis patients. Risk-centered approaches
have the potential to identify patients at highest risk for
SCD and test therapies for its prevention.
Additional file
Additional file 1: Supplemental Tables 1–4. (DOCX 21 kb)
Abbreviations
SCD: sudden cardiac death; NTproBNP: N-Terminal fragment of the
prohormone brain natriuretic peptide; cTnI: cardiac troponin I;
CHOICE: Choices for Healthy Outcomes in Caring for ESRD; DCI: Dialysis
Clinic, Inc.; CV: coefficient of variation; ICED: Index of Coexistent Disease;
BMI: Body mass index; NRI: net reclassification improvement; CMS: Center for
Medicare and Medicaid Services; HR: hazard ratio; CI: confidence interval.
Competing interests
Dr. Shafi reports receiving an honorarium from Siemens. Remaining authors
declare that they have no relevant financial interests.
CHOICE was supported by R01-HS-008365 (Agency for Healthcare Quality
and Research AHRQ) from 7/1994 to 6/1999, by RO1-HL-62985 (National
Heart, Lung, and Blood Institute (NHLBI) from 9/00 to 6/06, R01-DK-059616
(National Institute of Diabetes & Digestive & Kidney Diseases NIDDK) from
9/2000 to 6/2005 and by R01-DK-080123 from 8/2008 to 6/2015 (National
Institute of Diabetes & Digestive & Kidney Diseases NIDDK).
Authors’ contributions
RK and TS conceived the study design and drafted the manuscript. TS, AW,
SH conducted statistical analyses. All authors interpreted the data, read the
manuscript, made meaningful changes and approved the final manuscript.
Dr. Shafi was supported by K23-DK-083514 and National Kidney Foundation
of Maryland Professional Development Award.
Dr. Powe was supported by R01-DK-080123.
Research reported in this publication was supported by the National Institute
of Diabetes and Digestive and Kidney Diseases of the National Institutes of
Health. The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of Health.
The reagents for troponin I and NTproBNP were provided by Siemens to the
University of Maryland, where the measurements were performed. Siemens
had no role in the design, analysis, and interpretation of data or the
preparation of this manuscript.
Parts of this work were presented at the National Kidney Foundation’s Spring
Clinical Meeting April 22–26, 2014 at Las Vegas, NV.
Acknowledgement
We thank the patients, staff, laboratory, and physicians of Dialysis Clinic Inc.
(DCI) for their participation in the CHOICE Study.
We thank the Cardiovascular Endpoint Committee: Bernard G. Jaar, MD, MPH;
Michael J. Choi, MD; Josef Coresh, MD, PhD; Joseph A. Eustace, MD, MHS;
Nancy E. Fink, MPH; Caroline Fox, MD, MPH; Melanie H. Katzman, MD, MHS;
Michael J. Klag, MD, MPH; Yongmei Liu, MD, PhD; J. Craig Longenecker, MD,
PhD; Michal Melamed, MD, MHS; Laura C. Plantinga, ScM; Neil R. Powe, MD,
MPH, MBA; Renuka Sothinathan, MD, MHS; Richard M. Ugarte, MD, MHS and
Gayanne Yenokian, MD.
Author details
1Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
2Department of Medicine, Division of Cardiology, Hennepin County Medical
Center, University of Minnesota, Minneapolis, MN, USA. 3Department of
Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,,
MD, USA. 4Department of Biostatistics, Johns Hopkins Bloomberg School of
Public Health, Baltimore, MD, USA. 5Departments of Medicine and Pediatrics,
University of Toronto, Toronto, Canada. 6Welch Center for Prevention,
Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD,
USA. 7Department of Medicine, Division of Cardiology, Johns Hopkins
University, Baltimore, MD, USA. 8Department of Medicine, University of
California, San Francisco, CA, USA. 9Department of Medicine, Division of
Nephrology, Johns Hopkins University, 301 Mason Lord Drive, Suite, 2500
Baltimore, MD, USA.
Received: 15 June 2015 Accepted: 12 February 2016
References
1. U S Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States, National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD, 2013
2. Green D, Roberts PR, New DI, Kalra PA. Sudden cardiac death in hemodialysis
patients: an in-depth review. American journal of kidney diseases : the official
journal of the National Kidney Foundation. 2011;57(6):921–9.
3. Wang AY, Lam CW, Chan IH, Wang M, Lui SF, Sanderson JE. Sudden cardiac
death in end-stage renal disease patients: a 5-year prospective analysis.
Hypertension. 2010;56(2):210–6.
4. Paoletti E, Specchia C, Di Maio G, Bellino D, Damasio B, Cassottana P,
et al. The worsening of left ventricular hypertrophy is the strongest
predictor of sudden cardiac death in haemodialysis patients: a 10 year
survey. Nephrology, dialysis, transplantation : official publication of the
European Dialysis and Transplant Association - European Renal
Association. 2004;19(7):1829–34.
5. Sakhuja R, Shah AJ, Hiremath S, Thakur RK. End-stage renal disease and
sudden cardiac death. Cardiac Electrophysiology Clinics. 2009;1(1):61–77.
6. Parekh RS, Plantinga LC, Kao WH, Meoni LA, Jaar BG, Fink NE, et al. The
association of sudden cardiac death with inflammation and other traditional
risk factors. Kidney international. 2008;74(10):1335–42.
7. Davenport A, Sayed RH, Fan S. Is extracellular volume expansion of
peritoneal dialysis patients associated with greater urine output? Blood
Purif. 2011;32(3):226–31.
8. Sun L, Sun Y, Zhao X, Xu C, Chen D, Li L, et al. Predictive role of BNP and
NT-proBNP in hemodialysis patients. Nephron Clinical practice. 2008;110(3):
c178–184.
9. Winkler K, Wanner C, Drechsler C, Lilienthal J, Marz W, Krane V, et al. Change
in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death,
stroke, myocardial infarction, and all-cause mortality in diabetic dialysis
patients. European heart journal. 2008;29(17):2092–9.
10. Banerjee T, Kim SJ, Astor B, Shafi T, Coresh J, Powe NR. Vascular access type,
inflammatory markers, and mortality in incident hemodialysis patients: the
Choices for Healthy Outcomes in Caring for End-Stage Renal Disease
(CHOICE) Study. Am J Kidney Dis. 2014;64(6):954–61.
11. Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al.
Association of residual urine output with mortality, quality of life, and
inflammation in incident hemodialysis patients: the Choices for Healthy
Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J
Kidney Dis. 2010;56(2):348–58.
12. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in
survival analysis: model specific population value and confidence interval
estimation. Statistics in medicine. 2004;23(13):2109–23.
13. Pencina MJ, D'Agostino Sr RB, Steyerberg EW. Extensions of net
reclassification improvement calculations to measure usefulness of new
biomarkers. Statistics in medicine. 2011;30(1):11–21.
14. D'Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM,
et al. General cardiovascular risk profile for use in primary care: the
Framingham Heart Study. Circulation. 2008;117(6):743–53.
15. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of
goodness-of-fit tests for the logistic regression model. Statistics in medicine.
1997;16(9):965–80.
Kruzan et al. BMC Nephrology  (2016) 17:18 Page 10 of 11
16. Breidthardt T, Burton JO, Odudu A, Eldehni MT, Jefferies H, McIntyre CW.
N-terminal Pro-B-type natriuretic peptide and its correlation to
haemodialysis-induced myocardial stunning. Nephron Clinical practice.
2013;123(1–2):
118–22.
17. Papakrivopoulou E, Lillywhite S, Davenport A. Is N-terminal probrain-type
natriuretic peptide a clinically useful biomarker of volume overload in
peritoneal dialysis patients? Nephrology, dialysis, transplantation : official
publication of the European Dialysis and Transplant Association - European
Renal Association. 2012;27(1):396–401.
18. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac
troponin I and T for subsequent death in end-stage renal disease.
Circulation. 2002;106(23):2941–5.
19. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, et al.
Troponin is related to left ventricular mass and predicts all-cause and
cardiovascular mortality in hemodialysis patients. American journal of kidney
diseases : the official journal of the National Kidney Foundation. 2002;40(1):
68–75.
20. Michos ED, Berger Z, Yeh HC, Suarez-Cuervo C, Wilson LM, Stacy S, Bass EB:
Cardiac Troponins Used as Diagnostic and Prognostic Tests in Patients With
Kidney Disease. In: Cardiac Troponins Used as Diagnostic and Prognostic
Tests in Patients With Kidney Disease. Rockville (MD); 2014.
21. Cuschieri A, Adamson GD. Multimedia article. Laparoscopic transection
choledochoduodenostomy. Surgical endoscopy. 2005;19(5):728.
22. Adams 3rd JE, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson
JH, et al. Cardiac troponin I. A marker with high specificity for cardiac injury.
Circulation. 1993;88(1):101–6.
23. Abbas NA, John RI, Webb MC, Kempson ME, Potter AN, Price CP, et al.
Cardiac troponins and renal function in nondialysis patients with chronic
kidney disease. Clinical chemistry. 2005;51(11):2059–66.
24. Khan IA, Wattanasuwan N, Mehta NJ, Tun A, Singh N, Singh HK, et al.
Prognostic value of serum cardiac troponin I in ambulatory patients with
chronic renal failure undergoing long-term hemodialysis: a two-year
outcome analysis. Journal of the American College of Cardiology. 2001;
38(4):991–8.
25. Jaffe AS. Testing the wrong hypothesis: the failure to recognize the
limitations of troponin assays. Journal of the American College of
Cardiology. 2001;38(4):999–1001.
26. Goldstein BA, Chang TI, Mitani AA, Assimes TL, Winkelmayer WC. Near-term
prediction of sudden cardiac death in older hemodialysis patients using
electronic health records. Clin J Am Soc Nephrol. 2014;9(1):82–91.
27. Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP.
Chronic kidney disease is associated with increased risk of sudden cardiac
death among patients with coronary artery disease. Kidney Int. 2009;76(6):
652–8.
28. Hickson LJ, Gooden JY, Le KY, Baddour LM, Friedman PA, Hayes DL, et al.
Clinical presentation and outcomes of cardiovascular implantable electronic
device infections in hemodialysis patients. Am J Kidney Dis. 2014;64(1):
104–10.
29. Prutkin JM, Reynolds MR, Bao H, Curtis JP, Al-Khatib SM, Aggarwal S, et al.
Rates of and factors associated with infection in 200 909 Medicare
implantable cardioverter-defibrillator implants: results from the national
cardiovascular data registry. Circulation. 2014;130(13):1037–43.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kruzan et al. BMC Nephrology  (2016) 17:18 Page 11 of 11
